These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35672956)

  • 1. Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial.
    de Haan L; Linszen D; Wouters L; Zwinderman K; Dingemans P
    Psychol Med; 2023 Jul; 53(10):4316-4323. PubMed ID: 35672956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Specialised first-episode psychosis services: a systematic review of the literature].
    Skalli L; Nicole L
    Encephale; 2011 May; 37 Suppl 1():S66-76. PubMed ID: 21600336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients.
    Gleeson JF; Cotton SM; Alvarez-Jimenez M; Wade D; Gee D; Crisp K; Pearce T; Newman B; Spiliotacopoulos D; Castle D; McGorry PD
    J Clin Psychiatry; 2009 Apr; 70(4):477-86. PubMed ID: 19323964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
    Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
    Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.
    Wunderink L; van Bebber J; Sytema S; Boonstra N; Meijer RR; Wigman JTW
    Schizophr Res; 2020 Feb; 216():192-199. PubMed ID: 31866076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up.
    Gleeson JF; Cotton SM; Alvarez-Jimenez M; Wade D; Gee D; Crisp K; Pearce T; Spiliotacopoulos D; Newman B; McGorry PD
    Schizophr Bull; 2013 Mar; 39(2):436-48. PubMed ID: 22130905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
    Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
    CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis.
    Alvarez-Jiménez M; Parker AG; Hetrick SE; McGorry PD; Gleeson JF
    Schizophr Bull; 2011 May; 37(3):619-30. PubMed ID: 19900962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting antipsychotic medication as first-line treatment of first-episode psychosis with comorbid substance use disorder.
    Abdel-Baki A; Thibault D; Medrano S; Stip E; Ladouceur M; Tahir R; Potvin S
    Early Interv Psychiatry; 2020 Feb; 14(1):69-79. PubMed ID: 31125513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.
    Robinson D; Woerner MG; Alvir JM; Bilder R; Goldman R; Geisler S; Koreen A; Sheitman B; Chakos M; Mayerhoff D; Lieberman JA
    Arch Gen Psychiatry; 1999 Mar; 56(3):241-7. PubMed ID: 10078501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family environment and depressive episode are associated with relapse after first-episode psychosis.
    da Silva AHS; de Freitas LA; Shuhama R; Del-Ben CM; Vedana KGG; Martin IDS; Zanetti ACG
    J Psychiatr Ment Health Nurs; 2021 Dec; 28(6):1065-1078. PubMed ID: 33544947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
    Kishi T; Ikuta T; Matsui Y; Inada K; Matsuda Y; Mishima K; Iwata N
    Psychol Med; 2019 Apr; 49(5):772-779. PubMed ID: 29909790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
    Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
    Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP).
    Pelayo-Terán JM; Gajardo Galán VG; de la Ortiz-García de la Foz V; Martínez-García O; Tabarés-Seisdedos R; Crespo-Facorro B; Ayesa-Arriola R
    Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):315-323. PubMed ID: 27796500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprint of: Negative symptoms predict high relapse rates and both predict less favorable functional outcome in first episode psychosis, independent of treatment strategy.
    Wunderink L; van Bebber J; Sytema S; Boonstra N; Meijer RR; Wigman JTW
    Schizophr Res; 2020 Nov; 225():69-76. PubMed ID: 33279373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.
    Huhn M; Leucht C; Rothe P; Dold M; Heres S; Bornschein S; Schneider-Axmann T; Hasan A; Leucht S
    Eur Arch Psychiatry Clin Neurosci; 2021 Mar; 271(2):293-302. PubMed ID: 32062728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.